DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG Oncology Pulse

Stay on top of updates and innovations in the oncology landscape and how it impacts your decisions

Clinical Development Strategies for Checkpoint Inhibitors

View more

The Biosimilars Games: Who is Doing What and How in the Biosimilars Battlefield?

View more

Treatment Sequencing: Navigating the Complex System of Oncology Pathways

View more
Ask us your question

How are NSCLC Treatments Sequenced and What Factors Drive Prescribing?

View more
Ask us your question

Oncology Clinical Trial Monitor

View more

What is the U.S. Medical Community's Perception About CAR T-cell Therapies?

View more

EHA 2018: Shifting Paradigms in NHL

View more

ASCO Highlights and Industry Implications

View more

Avastin’s FDA Approval in First-line Ovarian Cancer

View more

Collaboration is Key to Accelerating Diagnostics Access to Precision Medicines

View more

Merck Set to Consolidate its Dominant Position in First-line Metastatic NSCLC

View more

Metastatic Castrate Resistant Prostate Cancer Global Forecast

View more

Mega-IDNs Rattle Payer Landscape: As Dominant Provider Systems Gain Control, MCOs...

View more

Oncology Team Extends Presence in Treatment Pathway with Epi and Claims Analysis

View more

Key IDN Insights for Pharma Planning

View more

Difficulties Developing Combinations with Immune Checkpoint Inhibitors

View more

The IDN Rundown for Pharma Strategists

View more

Immune Checkpoint Inhibitors - Late-Phase Trials Poised to Disrupt the Market

View more

Real-World Evidence Reveals Low Dosing Compliance in Multiple Myeloma

View more

Innovative Therapies for Bladder Cancer Outside of the Immune Space

View more

CAR T-cell Therapy Pipeline and Forecast Snapshot

View more

Under ISP, How Will your Plan Assess an Oncology Drug’s Value for an Indication?

View more

Last, But Not Least: KEYNOTE-045 in Bladder Cancer

View more

Phase III Epacadostat + Keytruda Trial Failure: Impact on the Oncology Landscape

View more

The Gastroesophageal Cancer Drug Market

View more

Infographic: What Global Oncologists Want from Pharma

View more